In a comparison of our study with the survival analysis performed on the Pathology Atlas database, ADGRE2, GALR3, DRD2, and CYP19A1 consistently displayed a trend of up-regulation in the group of CRC patients with poor prognosis. This evidence concerns the gene GALR3 and colorectal carcinoma.